Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 3, 2014, Pages 543-552

  Yokoyama, Keitaro ^a   Hirakata, Hideki ^b   Akiba, Takashi ^c   Fukagawa, Masafumi ^d   Nakayama, Masaaki ^e   Sawada, Kenichi ^f   Kumagai, Yuji ^g   Block, Geoffrey A ^h  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA RED CROSS HOSPITAL   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f AKITA UNIVERSITY   (Japan)

^g KITASATO UNIVERSITY HOSPITAL   (Japan)

^h Denver Nephrologists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CITRATE HYDRATE; FERRITIN; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DUODENUM ULCER; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEMATOPOIESIS; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST;

AGED; BIOLOGICAL MARKERS; CHELATING AGENTS; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; FERRITINS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; IRON; JAPAN; MALE; MIDDLE AGED; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 84896853425     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05170513     Document Type: Article

References (45)

1. Ritz E, Gross ML: Hyperphosphatemia in renal failure. Blood Purif 23: 6-9, 2005
2. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
3. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
4. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528, 2005
5. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
6. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E: Mineral metabolism parameters throughout chronic kidney disease stages 1-5- achievement of K/DOQI target ranges. Nephrol Dial Transplant 22: 1171-1176, 2007
7. Russo D, Corrao S, Miranda I, Ruocco C, Manzi S, Elefante R, Brancaccio D, Cozzolino M, Biondi ML, Andreucci VE: Progression of coronary artery calcification in predialysis patients. Am J Nephrol 27: 152-158, 2007
8. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20: 381-387, 2009
9. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112: 2627-2633, 2005
10. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O'Donoghue DJ, Middleton RJ, Kalra PA: Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5: 2251-2257, 2010
11. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Outcomes associated with serumphosphorus level inmaleswith non-dialysis dependent chronic kidney disease. Clin Nephrol 73: 268-275, 2010
12. Zoccali C, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Mallamaci F, Remuzzi G; REIN Study Group: Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 22: 1923-1930, 2011
13. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and BoneDisorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
14. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T; CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17: 247-288, 2013
15. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE: The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 72: 1255-1261, 2007
16. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders inmoderate CKD. J AmSoc Nephrol 23: 1407-1415, 2012
17. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan- Taber S, Heaton J, Duggal A, Kalra PA: Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 3: 1125-1130, 2008
18. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W: Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: A randomized trial. Clin J Am Soc Nephrol 4: 178-185, 2009
19. Tonelli M, Pannu N,Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 362: 1312-1324, 2010
20. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA; SPD405-309 Lanthanum Study Group: Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment. Nephron Clin Pract 110: c15-c23, 2008
21. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J; Collaborative StudyGroup: The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 121: c25-c29, 2012
22. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y: Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: Results of a randomized, double-blind, placebocontrolled trial. Am J Nephrol 36: 478-487, 2012
23. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009
24. Maroni BJ, Steinman TI, MitchWE: A method for estimating nitrogen intake of patientswith chronic renal failure. Kidney Int 27: 58-65,1985
25. Sim JJ, Bhandari SK, Smith N, Chung J, Liu IL, Jacobsen SJ, Kalantar-Zadeh K: Phosphorus and risk of renal failure in subjects with normal renal function. Am J Med 126: 311-318, 2013
26. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr., Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167: 879-885, 2007
27. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737-747, 2012
28. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA; European Uremic Toxin (EUTox) Work Group: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stage. Osteoporos Int 23: 2017-2025, 2012
29. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, König P, Kraatz G, Mann JF, Müller GA, Kö hler H, Riegler P; MMKD Study Group: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18: 2600-2608, 2007
30. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
31. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and endstage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
32. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
33. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T; ROD21 Clinical Research Group: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 9: 336-339, 2005
34. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
35. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A, Martinez- Calero A, Navas V, Rodriguez M, Ortiz A: Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 26: 2567-2571, 2011
36. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis 59: 177-185, 2012
37. Hryszko T, Rydzewska-Rosolowska A, Brzosko S, Koc-Zorawska E, Mysliwiec M: Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial 16: 146-151, 2012
38. Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, Fujimori A, Nishioka M, Nishi S, Fukagawa M: Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 33: 421-426, 2011
39. Wolf M, Koch TA, Bregman DB: Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28: 1793-1803, 2013
40. Drüeke TB, Parfrey PS: Summary of the KDIGO guideline on anemia and comment: Reading between the (guide)line(s). Kidney Int 82: 952-960, 2012
41. Nemeth E: Iron regulation and erythropoiesis. Curr Opin Hematol 15: 169-175, 2008
42. Kemna EH, Tjalsma H, Willems HL, Swinkels DW: Hepcidin: From discovery to differential diagnosis. Haematologica 93: 90-97, 2008
43. Vaziri ND: Understanding iron: Promoting its safe use in patients with chronic kidney failure treated by hemodialysis. AmJ Kidney Dis 61: 992-1000, 2013
44. Coburn JW, Mischel MG, Goodman WG, Salusky IB: Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 17: 708-711, 1991
45. Drüeke TB: Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant 17[Suppl 2]: 13-16, 2002